

*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the “**U.S. Securities Act**”) or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S under the U.S. Securities Act (“**Regulation S**”)) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws. There will be no public offering of securities in the United States. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the prospectus dated Wednesday, December 18, 2024 (the “**Prospectus**”) issued by Xunfei Healthcare Technology Co., Ltd. (訊飛醫療科技股份有限公司) (the “**Company**”) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information in the Prospectus.*

Unless otherwise defined in this announcement, capitalised terms used herein shall have the same meanings as those defined in the Prospectus.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong.

Potential investors of the Offer Shares should note that the Joint Sponsors and the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the paragraph headed “Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination” in the Prospectus at any time prior to 8: 00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on Monday, December 30, 2024).

*In connection with the Global Offering, Huatai Financial Holdings (Hong Kong) Limited, as stabilising manager (the “**Stabilising Manager**”), its affiliates or any person acting for it, on behalf of the Underwriters, may effect transactions with a view to stabilising or supporting the market price of the H Shares at a level higher than that which might otherwise prevail for a limited period on and after the Listing Date. However, there is no obligation on the Stabilising Manager, its affiliates or any person acting for it, to conduct any such stabilising action, which, if commenced, will be done at the sole and absolute discretion of the Stabilising Manager, its affiliates or any person acting for it, and may be discontinued at any time. Any such stabilising action is required to be brought to an end on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering, being Wednesday, January 22, 2025. Such stabilisation action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Cap. 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).*

Potential investors should be aware that stabilising action cannot be taken to support the price of the H Shares for longer than the stabilisation period which begins on the Listing Date and is expected to expire on Wednesday, January 22, 2025, being the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. After this date, no further stabilising action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.

訊飛醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

GLOBAL OFFERING

| | |
|--|--|
| Number of Offer Shares under the Global Offering | : 7,035,550 H Shares (subject to the Over-allotment Option) |
| Number of Hong Kong Offer Shares | : 703,600 H Shares (subject to reallocation) |
| Number of International Offer Shares | : 6,331,950 H Shares (subject to reallocation and the Over-allotment Option) |
| Offer Price | : HK\$82.8 per H Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund) |
| Nominal value | : RMB1.00 per H Share |
| Stock Code | : 2506 |

Joint Sponsors, Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers



Joint Bookrunners and Joint Lead Managers



Joint Lead Manager



IMPORTANT NOTICE TO INVESTORS OF HONG KONG OFFER SHARES

FULLY ELECTRONIC APPLICATION PROCESS

We have adopted a fully electronic application process for the Hong Kong Public Offering.

The Prospectus is available at the website of the Stock Exchange at www.hkexnews.hk under the “*HKEXnews > New Listings > New Listing Information*” section, and the website of the Company at www.iflyhealth.com. If you require a printed copy of the Prospectus, you may download and print from the website addresses above.

We will not provide any physical channels to accept any application for the Hong Kong Offer Shares by the public. The contents of the electronic version of the Prospectus are identical to the prospectus as registered with the Registrar of Companies in Hong Kong pursuant to Section 342C of the Companies (Winding Up and Miscellaneous Provisions) Ordinance.

To apply for the Hong Kong Offer Shares, you may:

- (1) apply online through the **HK eIPO White Form** service at www.hkeipo.hk; or
- (2) apply electronically through the **HKSCC EIPO** channel and cause HKSCC Nominees to apply on your behalf by instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic application instructions** via HKSCC’s FINI system to apply for the Hong Kong Offer Shares on your behalf.

If you are an **intermediary, broker** or **agent**, please remind your customers, clients or principals, as applicable, that the Prospectus is available online at the website addresses stated above.

See the section headed “How to Apply for Hong Kong Offer Shares” in the Prospectus for further details of the procedures through which you can apply for the Hong Kong Offer Shares.

Your application through the **HK eIPO White Form** service or the **HKSCC EIPO** channel must be made for a minimum of 50 Hong Kong Offer Shares and in multiples of that number of Hong Kong Offer Shares as set out in the table below.

If you are applying through the **HK eIPO White Form** service, you may refer to the table below for the amount payable for the number of Hong Kong Offer Shares you have selected. You must pay the respective amount payable on application in full upon application for Hong Kong Offer Shares.

If you are applying through the **HKSCC EIPO** channel, you are required to pre-fund your application based on the amount specified by your **broker** or **custodian**, as determined based on the applicable laws and regulations in Hong Kong.

| No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment HK\$ | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment HK\$ | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment HK\$ | No. of Hong Kong Offer Shares applied for | Amount payable ⁽²⁾ on application/ successful allotment HK\$ |
|--|--|--|--|--|--|--|--|
| 50 | 4,181.75 | 800 | 66,908.03 | 7,000 | 585,445.27 | 100,000 | 8,363,503.80 |
| 100 | 8,363.50 | 900 | 75,271.53 | 8,000 | 669,080.30 | 200,000 | 16,727,007.60 |
| 150 | 12,545.26 | 1,000 | 83,635.04 | 9,000 | 752,715.34 | 300,000 | 25,090,511.40 |
| 200 | 16,727.01 | 1,500 | 125,452.56 | 10,000 | 836,350.38 | 351,800 ⁽¹⁾ | 29,422,806.36 |
| 250 | 20,908.76 | 2,000 | 167,270.08 | 20,000 | 1,672,700.75 | | |
| 300 | 25,090.51 | 2,500 | 209,087.60 | 30,000 | 2,509,051.15 | | |
| 350 | 29,272.26 | 3,000 | 250,905.11 | 40,000 | 3,345,401.52 | | |
| 400 | 33,454.01 | 3,500 | 292,722.62 | 50,000 | 4,181,751.90 | | |
| 450 | 37,635.78 | 4,000 | 334,540.15 | 60,000 | 5,018,102.28 | | |
| 500 | 41,817.52 | 4,500 | 376,357.67 | 70,000 | 5,854,452.65 | | |
| 600 | 50,181.02 | 5,000 | 418,175.19 | 80,000 | 6,690,803.05 | | |
| 700 | 58,544.52 | 6,000 | 501,810.23 | 90,000 | 7,527,153.42 | | |

Notes:

- (1) Maximum number of Hong Kong Offer Shares you may apply for and this is 50% of the Hong Kong Offer Shares initially offered.
- (2) The amount payable is inclusive of brokerage, SFC transaction levy, the Stock Exchange trading fee and AFRC transaction levy. If your application is successful, brokerage will be paid to the Exchange Participants (as defined in the Listing Rules) or to the **HK eIPO White Form** Service Provider (for applications made through the application channel of the **HK eIPO White Form** Service Provider) while the SFC transaction levy, the Stock Exchange trading fee and the AFRC transaction levy will be paid to the SFC, the Stock Exchange and the AFRC, respectively.

No application for any other number of Hong Kong Offer Shares will be considered and such an application is liable to be rejected.

THE LISTING APPLICATION

The Company has applied to the Stock Exchange for the granting of listing of, and permission to deal in, the H Shares to be issued pursuant to the Global Offering (including the H Shares to be converted from the Unlisted Shares and any H Shares which may be issued pursuant to the exercise of the Over-allotment Option). Assuming that the Hong Kong Public Offering becomes unconditional at or before 8: 00 a.m. in Hong Kong on Monday, December 30, 2024, dealings in the H Shares on the Stock Exchange are expected to commence at 9: 00 a.m. in Hong Kong on Monday, December 30, 2024.

STRUCTURE OF THE GLOBAL OFFERING

The Global Offering comprises:

- the Hong Kong Public Offering of initially 703,600 Offer Shares (subject to reallocation) representing approximately 10.0% of the total number of Offer Shares available under the Global Offering, and
- the International Offering of initially 6,331,950 Offer Shares (subject to reallocation and the Over-allotment Option), representing approximately 90.0% of the total number of Offer Shares available under the Global Offering.

The allocation of the Offer Shares between the Hong Kong Public Offering and the International Offering will be subject to reallocation and the Over-allotment Option as described in the section headed “Structure of the Global Offering” in the Prospectus.

In particular, subject to the requirements under Practice Note 18 to the Listing Rules and Chapter 4.14 (Offering-related Mechanisms) of the Guide, the Overall Coordinators may, at their sole discretion, reallocate Offer Shares from the International Offering to the Hong Kong Public Offering to satisfy valid applications under the Hong Kong Public Offering. In accordance with Chapter 4.14 (Offering-related Mechanisms) of the Guide, in the event that (i) the International Offer Shares are undersubscribed and the Hong Kong Offer Shares are fully subscribed or oversubscribed irrespective of the number of times; or (ii) the International Offer Shares are fully subscribed or oversubscribed and the Hong Kong Offer Shares are fully subscribed or oversubscribed as to less than 15 times of the number of Hong Kong Offer Shares initially available under the Hong Kong Public Offering, then the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) may only reallocate Offer Shares from the International Offering to the Hong Kong Public Offering other than pursuant to Practise Note 18 of the Listing Rules, the total number of Offer Shares available under the Hong Kong Public Offering following such reallocation shall be 1,407,150 Offer Shares (representing approximately 20% of the Offer Shares initially available under the Global Offering).

PRICING

The Offer Price will be HK\$82.8 per Offer Share, unless otherwise announced, as further explained in the section headed “Structure of the Global Offering” in the Prospectus. Applicants under the Hong Kong Public Offering are required to pay, on application (subject to application channels), the Offer Price of HK\$82.8 per Offer Share plus brokerage of 1.0%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015%, amounting to a total of HK\$4,181.75 for one board lot of 50 H Shares.

EXPECTED TIMETABLE

Hong Kong Public Offering commences 9: 00 a.m. on
Wednesday, December 18, 2024

Latest time to complete electronic applications under
the **HK eIPO White Form** service through
the designated website at www.hkeipo.hk 11: 30 a.m. on
Monday, December 23, 2024

Application lists open 11: 45 a.m. on
Monday, December 23, 2024

Latest time to give **electronic application instructions** to
HKSCC 12: 00 noon on
Monday, December 23, 2024

Latest time to complete payment of **HK eIPO White
Form** applications by effecting internet banking
transfer(s) or PPS payment transfer(s). 12: 00 noon on
Monday, December 23, 2024

If you are instructing your **broker** or **custodian** who is a HKSCC Participant to give **electronic
application instructions** via FINI to apply for the Hong Kong Offer Shares on your behalf, you
are advised to contact your **broker** or **custodian** for the latest time for giving such instructions
which may be different from the latest time as stated above.

Application lists close 12: 00 noon on
Monday, December 23, 2024

(1) Announcement of:

- the level of applications in the Hong Kong Public Offering;
- the level of indications of interest in the International Offering; and
- the basis of allocation of the Hong Kong Offer Shares

to be published on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.iflyhealth.com

..... at or before 11:00 p.m. on Friday, December 27, 2024

(2) Results of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) to be made available through a variety of channels as described in the section headed "How to Apply for Hong Kong Offer Shares — B. Publication of Results" in the Prospectus

..... at or before 11:00 p.m. on Friday, December 27, 2024

(3) A full announcement of the Hong Kong Public Offering containing (1) and (2) above to be published on the website of the Stock Exchange at www.hkexnews.hk and the Company's website at www.iflyhealth.com

..... at or before 11:00 p.m. on Friday, December 27, 2024

Result of allocations in the Hong Kong Public Offering (with successful applicants' identification document numbers, where appropriate) will be available at the "Allotment Results" page at www.hkeipo.hk/IPOResult or www.tricor.com.hk/ipo/result with a "search by ID" function from

..... 11:00 p.m. on Friday, December 27, 2024

H Share certificates in respect of wholly or partially successful applications to be dispatched or deposited into CCASS on or before.

..... Friday, December 27, 2024

HK eIPO White Form e-Auto Refund payment instructions/refund cheques in respect of wholly or partially unsuccessful applications pursuant to the Hong Kong Public Offering to be dispatched on or before

..... Monday, December 30, 2024

Dealings in the H Shares on the Stock Exchange

expected to commence at. 9: 00 a.m.

Monday, December 30, 2024

SETTLEMENT

Subject to the granting of the listing of, and permission to deal in, the H Shares on the Stock Exchange and the Company's compliance with the stock admission requirements of HKSCC, the H Shares will be accepted as eligible securities by HKSCC for deposit, clearance and settlement in CCASS with effect from the date of commencement of dealings in the H Shares on the Stock Exchange or any other date HKSCC chooses. Settlement of transactions between Exchange Participants (as defined in the Listing Rules) is required to take place in CCASS on the second settlement day after any trading day. All activities under CCASS are subject to the General Rules of HKSCC and the HKSCC Operational Procedures in effect from time to time. Investors should seek the advice of their stockbroker or other professional advisor for details of the settlement arrangements as such arrangements may affect their rights and interests. All necessary arrangements have been made for enabling the H Shares to be admitted into CCASS.

ELECTRONIC APPLICATION CHANNELS

The Hong Kong Public Offering period will begin at 9: 00 a.m. on Wednesday, December 18, 2024 and end at 12: 00 noon on Monday, December 23, 2024 (Hong Kong time).

To apply for Hong Kong Offer Shares, you may use one of the following application channels:

| Application Channel | Platform | Target Investors | Application Time |
|----------------------------|--|---|---|
| HK eIPO White Form service | www.hkeipo.hk | Investors who would like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in your own name. | From 9: 00 a.m. on Wednesday, December 18, 2024 to 11: 30 a.m. on Monday, December 23, 2024, Hong Kong time. The latest time for completing full payment of application monies will be 12: 00 noon on Monday, December 23, 2024, Hong Kong time. |

| Application Channel | Platform | Target Investors | Application Time |
|---------------------------|--|--|---|
| HKSCC EIPO channel | Your broker or custodian who is an HKSCC Participant will submit an EIPO application on your behalf through HKSCC's FINI system in accordance with your instruction. | Investors who would <u>not</u> like to receive a physical H Share certificate. Hong Kong Offer Shares successfully applied for will be allotted and issued in the name of HKSCC Nominees, deposited directly into CCASS and credited to your designated HKSCC Participant's stock account. | Contact your broker or custodian for the earliest and latest time for giving such instructions, as this may vary by broker or custodian . |

The **HK eIPO White Form** service and the **HKSCC EIPO** channel are facilities subject to capacity limitations and potential service interruptions and you are advised not to wait until the last day of the application period to apply for Hong Kong Offer Shares.

For those applying through the **HK eIPO White Form** service, the application monies (including brokerage, SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy) will be held by the **HK eIPO White Form** Service Provider on behalf of the Company and the refund monies, if any, will be returned to you without interest on Monday, December 30, 2024.

For those applying through the **HKSCC EIPO** channel, your **broker** or **custodian** will arrange the refund monies, if any, to your designated bank account subject to the arrangement application monies paid between you and it.

Please refer to the sections headed "Structure of the Global Offering" and "How to Apply for Hong Kong Offer Shares" in the Prospectus for details of the conditions and procedures of the Hong Kong Public Offering.

Application for the Hong Kong Offer Shares will only be considered on the basis of the terms and conditions set out in the Prospectus and on the designated website at www.hkeipo.hk for the HK eIPO White Form service.

PUBLICATION OF RESULTS

The Company expects to announce the level of indications of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares on Friday, December 27, 2024 on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.iflyhealth.com.

The results of allocations and the identification document numbers of successful applicants under the Hong Kong Public Offering will be available through a variety of channels at the times and date and in the manner specified in the section headed “How to Apply for Hong Kong Offer Shares — B. Publication of Results” in the Prospectus.

If an application is rejected, not accepted or accepted in part only, or if the conditions of the Hong Kong Public Offering as set out in the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus are not satisfied or if any application is revoked, the application monies, or the appropriate portion thereof, together with the related brokerage, SFC transaction levy, Stock Exchange trading fee and AFRC transaction levy, will be refunded (subject to application channels), without interest, as described in the section headed “How to Apply for Hong Kong Offer Shares — D. Despatch/Collection of H Share Certificates and Refund of Application Monies” in the Prospectus.

No temporary document of title will be issued in respect of the Offer Shares. No receipt will be issued for sums paid on application. H Share certificates will only become valid evidence of title provided that (i) the Global Offering has become unconditional in all respects and (ii) neither the Hong Kong Underwriting Agreement nor the International Underwriting Agreement has been terminated in accordance with their terms prior to 8: 00 a.m. on Monday, December 30, 2024. Investors who trade H Shares on the basis of publicly available allocation details or prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Hong Kong Public Offering becomes unconditional at or before 8: 00 a.m. in Hong Kong on Monday, December 30, 2024, it is expected that dealings in the H Shares on the Stock Exchange will commence at 9: 00 a.m. on Monday, December 30, 2024. The H Shares will be traded in board lots of 50 H Shares each and the stock code of the H Shares will be 2506.

This announcement is available for viewing on the websites of the Stock Exchange at www.hkexnews.hk and the Company at www.iflyhealth.com.

By order of the Board
Xunfei Healthcare Technology Co., Ltd.
Dr. Tao Xiaodong
Executive Director

Hong Kong, December 18, 2024

Directors of the Company named in the application to which this announcement relates are: (i) Dr. Tao Xiaodong as executive director; (ii) Dr. Liu Qingfeng, Mr. Zhao Zhiwei and Mr. Duan Dawei as non-executive directors; and (iii) Prof. Wang Yang, Prof. Zhao Huifang and Mr. Tan Ching as independent non-executive directors.